当前位置: 首页 > 期刊 > 《中国当代医药》 > 2019年第26期
编号:13406982
FOXA1与AMACR/P504s在前列腺癌中的表达及其临床意义(4)
http://www.100md.com 2019年9月15日 《中国当代医药》 2019年第26期
     [15]Kumaresan K,Kakkar N,Verma A,et al.Diagnostic utility of α-methylacyl CoA racemase (P504S) & HMWCK in morphologically difficult prostate cancer[J].Diagn Pathol,2010, 5(1):83.

    [16]Yan Q,Zhang XR,Zhang Z,et al.Prevalence of protein C receptor(PROCR)is associated with inferior clinical outcome in Breast invasive ductal carcinoma[J].Pathol Res Pract,2017,213(9):1173-1179.

    [17]Kim J,Jin H,Zhao JC,et al.FOXA1 inhibits prostate cancer neuroendocrine differentiation[J].Oncogene,2017,36(28):4072-4080.

    [18]Mirosevich J,Gao N,Gupta A,et al.Expression and role of Foxa proteins in prostate cancer[J].Prostate,2006,66(10):1013-1028.

    [19]Jain D,Gupta S,Marwah N,et al.Evaluation of role of alpha-methyl acyl-coenzyme A racemase/P504S and high molecular weight cytokeratin in diagnosing prostatic lesions[J].J Cancer Res Ther,2017,13(1):21-25.

    [20]Luo J,Zha S,Gage WR,et al.Alpha-methylacyl-CoA racemase:a new molecular marker for prostate cancer[J].Cancer Res,2002,62(8):2220-2226.

    [21]Wu CL,Yang XJ,Tretiakova M,et al.Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia[J].Hum Pathol,2004,35(8):1008-1013.

    (收稿日期:2019-03-06 本文編辑:任秀兰), 百拇医药(张继君 石晓欣 陶丽丽 陈耀丽 赵昌林)
上一页1 2 3 4